Clinical Trial Update: A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment. [Phase 2]

View source ↗

Summary

A Phase 2 clinical study evaluating SSGJ-613 in gout patients initiating urate-lowering therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• SSGJ-613

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Gout Arthritis | Phase 2 | Status: UNKNOWN